Daniel Thomas

At CES 2026, Ubicept's new toolkit promises to let AI see clearly in the dark and at high speed, ushering in a new era for robotics and autonomous cars.

A new drug could redefine life for polycythemia vera patients, replacing frequent, burdensome blood draws with a simple weekly self-injection.

A new collaboration brings a sci-fi concept to life, promising to transform car interiors and safety for the coming age of personal autonomous vehicles.

China's JIADE LIMITED partners with South Korea's Chinalink, leveraging AI to expand education services to North America, Asia, and the Middle East.

In a move reflecting industry consolidation, GCE Global Solutions acquires GCE Payroll Advisers to deepen its compliance and cross-border payroll capabilities.

Pending home sales soared in November, hitting a multi-year high. Is this the turning point buyers and sellers have been waiting for? We break it down.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

Amid rising community need, a local firm's two-decade commitment provides a critical lifeline for an 80-year-old charity ensuring no one is left behind.

eXp Realty's new partnership with Land id gives agents advanced mapping tools, promising to reshape property analysis and set new industry standards.

Former IBERIABANK CEO Daryl Byrd is back, leading a $250M investment to transform M C Bank into a regional powerhouse. Here’s what it means for Louisiana.

With social engineering attacks that trick users into copying malicious code up over 500%, a new tool aims to stop them by securing the browser itself.

New data shows Vyriad's VV169 eliminated myeloma in mice without severe toxicity, signaling a potential shift to safer, scalable 'off-the-shelf' CAR T.

Private equity giant Apollo is acquiring French food retailer Prosol. A deep dive into the deal, Prosol's unique model, and the future of food retail.

Quebec food distributor Colabor Group fails to secure a financial lifeline, risking creditor protection and threatening a major regional supply chain disruption.

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

FDA greenlights the first precision therapy for BRCA2-mutated mCSPC, a highly aggressive prostate cancer, slashing progression risk by 54%.

AIP Realty Trust's $78.7M acquisition of AllTrades pivots on a complex related-party deal and reverse takeover, putting unitholder trust to the test.

BlackRock's latest fund distributions reveal a heavy reliance on 'return of capital,' especially in its resource funds. What does this mean for investors?

The safari park operator swung from a major loss to a $1.9M pre-tax profit, driven by revenue growth and the absence of prior-year proxy battle costs.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.